The Legacy Of The Egg: How Maternal Factors Set Offspring Health And Lifecourse Potential
Funder
National Health and Medical Research Council
Funding Amount
$697,605.00
Summary
Before an oocyte is fertilised, it contains all the material needed to form an embryo, and a legacy of information about its environment. My research aims to discover how oocyte signals, accumulated before conception, determine the health of the future individual; and then harness this knowledge to improve female reproductive health and generate new approaches to treat infertility and to optimise healthy embryo development in all pregnancies.
The aim of this project is to determine whether melatonin supplementation has an effect on cumulative pregnancy and delivery rates, allowing for the use of frozen embryos obtained during a melatonin treatment cycle. This will be achieved by a series of experiments designed to investigate the effect of melatonin on follicular fluid and culture media as well as assessing clinical pregnancy rates and delivery rates.
Understanding Idiopathic Male Infertility: Biomarkers To Assist In The Diagnosis And Assisted Reproductive Technology Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$411,012.00
Summary
In order to help in the diagnosis of male infertility, we have found several biomarkers that can be readily and quickly used to determine if a mans spermatozoa are infertile. Not only will this save time and money for couples involved in IVF, but help to avoid unnecessary, often invasive medical procedures that are currently used.
Investigation Of The Mechanisms Underpinning HSPA2 Dysfunction In The Spermatozoa Of Infertile Patients
Funder
National Health and Medical Research Council
Funding Amount
$481,563.00
Summary
Male infertility is an extremely common condition, that is frequently associated with the production of sperm that have lost their ability to recognize the egg. We have shown that this defect is frequently associated with a deficiency in a specific protein (HSPA2). By determining the mechanisms underpinning the loss of HSPA2, this project will provide powerful insights into the causes of male infertility, with practical implications for prevention, diagnosis and treatment of this condition.
Development Of A Novel Microfluidic Device To Treat Male Infertility
Funder
National Health and Medical Research Council
Funding Amount
$508,397.00
Summary
This research aims to develop a novel technology for the separation of high quality sperm. It is envisaged this will replace existing technology to improve the reproductive outcomes of both humans, as well as animals.
A BubR1-centred Network For Non-invasively Measuring Human Oocyte Quality
Funder
National Health and Medical Research Council
Funding Amount
$532,207.00
Summary
Oocyte quality is the most important determinant of pregnancy outcome. Selecting the best oocytes for fertility treatments like IVF would therefore greatly improve success rates and reduce costs. We have identified master oocyte regulators and have applied novel digital technology to measure these regulators in a single oocyte. This project will apply this expertise to develop new approaches for evaluating an oocyte’s potential thereby informing its suitability for use in fertility treatment.
Nicotinamide Adenine Dinucleotide (NAD+)-raising Agents For Improving Oocyte Quality
Funder
National Health and Medical Research Council
Funding Amount
$445,827.00
Summary
Many women cannot have children because of suboptimal egg quality, often due to aging. Currently, the only option is to use better quality eggs donated from another woman. This project will use pharmacological agents to promote recently discovered pathways in eggs central to determining quality. Importantly, we will investigate a simple and practical approach that can be used in clinics for augmenting these pathways to improve oocyte quality for the first time.
EGF Peptide Signalling Improves Oocyte Maturation And Quality
Funder
National Health and Medical Research Council
Funding Amount
$586,891.00
Summary
Infertility is common and although IVF is widely accepted, the procedure is expensive and is associated with health risks. Using laboratory animals, we have developed significant new insights into mechanisms regulating egg quality. These insights have allowed us to develop a new approach to infertility treatment - crucially, one that eliminates the need for ovarian hormone therapy used in IVF. This project will investigate the basic mechanisms underlying our new approach to enable safe clinical ....Infertility is common and although IVF is widely accepted, the procedure is expensive and is associated with health risks. Using laboratory animals, we have developed significant new insights into mechanisms regulating egg quality. These insights have allowed us to develop a new approach to infertility treatment - crucially, one that eliminates the need for ovarian hormone therapy used in IVF. This project will investigate the basic mechanisms underlying our new approach to enable safe clinical implementation.Read moreRead less
A Novel Procedure For Efficacious Gonadotrophin-free Infertility Treatment
Funder
National Health and Medical Research Council
Funding Amount
$436,328.00
Summary
Infertility is common and is associated with health risks and is expensive. Using laboratory animals, we have developed a unique procedure, which has comparable success rates to IVF but crucially, it eliminates the need for ovarian hormone therapy used in IVF. A clinical trial using this method has started in Brussels and in this project we will examine cells from that trial and from animals to investigate the underlying mechanisms to enable safe and rapid clinical implementation.
Infertility is common and although IVF is widely accepted, the procedure is expensive and is associated with health risks. Using laboratory animals, we have made significant advances towards developing new technologies that can mature eggs and produce embryos in vitro, but without women receiving hormone injections. This project will seek means to combine the benefits of two of our existing technologies into one integrated system, to provide hormone-free infertility treatment.